Lifevantage Corp.

LFVN

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000849146

B/C

on the B/C boundary of 367 graded peers in healthcare

rank 152 of 367; percentile 41.3; sampling error 2.5 points; lower is stronger

A B C D E

B/C, the elk



Scoreboard	
Profitability	B percentile 24.1
Solvency	C/D percentile 58.6
Growth and financing	C percentile 55.5
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $62.1M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: short runway, distress, fortress balance sheet
Inputs computable	10 of 14
Graded from	filings received through Aug 27, 2026 80 days before the rescan; latest periodic filing 10-Q received Nov 9, 2026
Last close	$5.00 2026-11-13; market equity $63.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Aug 27, 2026

LifeVantage Corporation (the "Company," "LifeVantage," "we," "us," or "our") is a company focused on nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. LifeVantage is dedicated to helping people achieve their health, wellness and financial goals. We provide quality, scientifically validated products to customers and independent consultants as well as a financially rewarding commission-based direct sales opportunity to our independent consultants.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 24.1						
Gross profitability	228.0%	32.3%		0.8	365	2026-06-30
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(7.7%)	(6.6%)		51.3	799	2026-06-30

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	1.3 pts	2.8 pts	20.3	242	2026-06-30
Solvency, sleeve percentile 58.6					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(1.63)	(0.31)	43.9	743	2026-06-30
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2024-06-30; latest annual assets end 2026-06-30					
Current ratio	1.89x	2.96x	73.2	825	2026-06-30
Growth and financing, sleeve percentile 55.5					
Revenue growth, three-year compound	(5.1%)	10.1%	80.0	411	2026-06-30
Free cash flow growth, three-year compound	21.0%	11.0%	42.6	95	2026-06-30
Reinvestment rate	(94.3%)	37.1%	90.3	104	2026-06-30
Asset growth, three years	(2.1%)	2.3%	56.5	693	2026-06-30
Net share issuance, one year	(1.3%)	2.4%	8.0	627	2026-08-26

Among 367 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
147	Celldex Therapeutics, Inc. (CLDX)	39.9	B/C	short runway
148	Myomo, Inc. (MYO)	40.2	B/C	fortress balance sheet
149	Lensar, Inc. (LNSR)	40.4	B/C	
150	Pacira BioSciences, Inc. (PCRX)	40.7	B/C	
151	Medtronic plc (MDT)	41.0	B/C	
152	Lifevantage Corp. (LFVN)	41.3	B/C	
153	Community Health Systems Inc. (CYH)	41.5	B/C	
154	Xeris Biopharma Holdings, Inc. (XERS)	41.8	B/C	
155	Envista Holdings Corp. (NVST)	42.1	B/C	
156	Nephros Inc. (NEPH)	42.3	B/C	fortress balance sheet
157	Sight Sciences, Inc. (SGHT)	42.6	C	fortress balance sheet

What the price implies

at the 2026-11-13 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(21.3%)	(1.5%)	36
Distance from 52-week high	(53.6%)	(32.0%)	28
EBIT to enterprise value	7.4%	(1.8%)	86
Free cash flow yield	10.6%	(1.0%)	91
Book value to price	0.53	0.29	70
Sales to price	2.90	0.29	94
Composite equity issuance, five years	(22.7%)	19.1%	7

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Relative strength against the sector, log excess return	(0.41)	(0.18)	36

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-06-30	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	6 (10-Q received Nov 9, 2026)
Median daily dollar volume, 63 sessions	$192,852

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$141.6M	2026-06-30	2026-08-27	10-K	26-371257
2	assets	us-gaap:Assets	$62.1M	2026-06-30	2026-08-27	10-K	26-371257
3	net income	us-gaap:NetIncomeLoss	$5.1M	2026-06-30	2026-08-27	10-K	26-371257
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$10.2M	2026-06-30	2026-08-27	10-K	26-371257
5	assets	us-gaap:Assets	$72.0M	2025-06-30	2026-08-27	10-K	26-371257
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$182.6M	2026-06-30	2026-08-27	10-K	26-371257
7	gross profit	us-gaap:GrossProfit	$183.7M	2025-06-30	2026-08-27	10-K	26-371257
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$228.5M	2025-06-30	2026-08-27	10-K	26-371257
9	gross profit	us-gaap:GrossProfit	$158.7M	2024-06-30	2025-09-04	10-K	25-000068
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$200.2M	2024-06-30	2025-09-04	10-K	25-000068
11	gross profit	us-gaap:GrossProfit	$170.0M	2023-06-30	2024-08-28	10-K	24-000073
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$213.4M	2023-06-30	2024-08-28	10-K	24-000073
13	gross profit	us-gaap:GrossProfit	$168.3M	2022-06-30	2023-08-28	10-K	23-000102
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$206.4M	2022-06-30	2023-08-28	10-K	23-000102
15	current assets	us-gaap:AssetsCurrent	$38.3M	2026-06-30	2026-08-27	10-K	26-371257
16	current liabilities	us-gaap:LiabilitiesCurrent	$20.2M	2026-06-30	2026-08-27	10-K	26-371257
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$103.5M	2026-06-30	2026-08-27	10-K	26-371257
18	operating income	us-gaap:OperatingIncomeLoss	$6.1M	2026-06-30	2026-08-27	10-K	26-371257
19	book equity	us-gaap:StockholdersEquity	$33.6M	2026-06-30	2026-08-27	10-K	26-371257
20	liabilities	us-gaap:Liabilities	$28.5M	2026-06-30	2026-08-27	10-K	26-371257
21	operating income	us-gaap:OperatingIncomeLoss	$4.3M	2024-06-30	2025-09-04	10-K	25-000068
22	interest expense	us-gaap:InterestExpense	-$430,000	2024-06-30	2024-08-28	10-K	24-000073
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.6M	2026-06-30	2026-08-27	10-K	26-371257
24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$11.9M	2025-06-30	2026-08-27	10-K	26-371257
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.4M	2025-06-30	2026-08-27	10-K	26-371257
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$12.2M	2024-06-30	2025-09-04	10-K	25-000068
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2.2M	2024-06-30	2025-09-04	10-K	25-000068
28	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$6.8M	2023-06-30	2024-08-28	10-K	24-000073
29	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$3.1M	2023-06-30	2024-08-28	10-K	24-000073
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$2.8M	2026-06-30	2026-08-27	10-K	26-371257

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$6.1M	2026-06-30	2026-08-27	10-K	26-371257
32	income tax	us-gaap:IncomeTaxExpenseBenefit	$994,000	2026-06-30	2026-08-27	10-K	26-371257
33	current assets	us-gaap:AssetsCurrent	$50.9M	2025-06-30	2026-08-27	10-K	26-371257
34	current liabilities	us-gaap:LiabilitiesCurrent	$27.2M	2025-06-30	2026-08-27	10-K	26-371257
35	assets	us-gaap:Assets	$60.3M	2024-06-30	2025-09-04	10-K	25-000068
36	assets	us-gaap:Assets	$66.1M	2023-06-30	2024-08-28	10-K	24-000073
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,527,348	2026-08-26	2026-08-27	10-K	26-371257
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	12,691,009	2025-09-03	2025-09-04	10-K	25-000068

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.